ASCO GU 2024-话题@MedSci

#ASCO GU 2024#

0篇内容 | 721人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2184849, encodeId=3e962184849d7, content=<a href='/topic/show?id=9d4a1102e995' target=_blank style='color:#2F92EE;'>#高危前列腺癌#</a> <a href='/topic/show?id=c193110640f1' target=_blank style='color:#2F92EE;'>#ASCO GU 2024#</a> <a href='/topic/show?id=dc1b11069e62' target=_blank style='color:#2F92EE;'>#大剂量放射治疗#</a>, objectTitle=ASCO GU 2024：大剂量放射治疗或可延长高危前列腺癌患者的生存期, objectType=article, longId=811595, objectId=69cd811595a7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240128/1706443016945_8624274.png, objectUrl=/article/show_article.do?id=69cd811595a7, replyNumber=0, likeNumber=103, createdTime=2024-01-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=69cd811595a7, moduleTitle=ASCO GU 2024：大剂量放射治疗或可延长高危前列腺癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69cd811595a7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184924, encodeId=4b382184924c3, content=<a href='/topic/show?id=40d882430a0' target=_blank style='color:#2F92EE;'>#肾上腺癌#</a> <a href='/topic/show?id=c193110640f1' target=_blank style='color:#2F92EE;'>#ASCO GU 2024#</a>, objectTitle=2024 ASCO GU｜肾上腺癌重磅研究出击，速览最新进展！, objectType=article, longId=811180, objectId=eea6811180f5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867668820_4754896.png, objectUrl=/article/show_article.do?id=eea6811180f5, replyNumber=0, likeNumber=70, createdTime=2024-01-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=eea6811180f5, moduleTitle=2024 ASCO GU｜肾上腺癌重磅研究出击，速览最新进展！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eea6811180f5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184586, encodeId=64e7218458613, content=<a href='/topic/show?id=d3b326916c3' target=_blank style='color:#2F92EE;'>#依维莫司#</a> <a href='/topic/show?id=25a21106626c' target=_blank style='color:#2F92EE;'>#Belzutifan#</a> <a href='/topic/show?id=c193110640f1' target=_blank style='color:#2F92EE;'>#ASCO GU 2024#</a> <a href='/topic/show?id=825911066391' target=_blank style='color:#2F92EE;'>#晚期RCC#</a>, objectTitle=ASCO GU 2024：Belzutifan与依维莫司对晚期RCC的疗效：LITESPARK-005 3 期研究中的患者报告结果 (PROs), objectType=article, longId=811387, objectId=195281138e2f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240128/1706443016945_8624274.png, objectUrl=/article/show_article.do?id=195281138e2f, replyNumber=0, likeNumber=65, createdTime=2024-01-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=195281138e2f, moduleTitle=ASCO GU 2024：Belzutifan与依维莫司对晚期RCC的疗效：LITESPARK-005 3 期研究中的患者报告结果 (PROs), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=195281138e2f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184487, encodeId=eb40218448e9f, content=<a href='/topic/show?id=1417e308648' target=_blank style='color:#2F92EE;'>#睾丸癌#</a> <a href='/topic/show?id=594853956a' target=_blank style='color:#2F92EE;'>#ctDNA#</a> <a href='/topic/show?id=c193110640f1' target=_blank style='color:#2F92EE;'>#ASCO GU 2024#</a>, objectTitle=ASCO GU 2024：ctDNA有望在睾丸癌预后评估方面发挥更精准的管理价值, objectType=article, longId=811383, objectId=5f0581138308, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240128/1706443016945_8624274.png, objectUrl=/article/show_article.do?id=5f0581138308, replyNumber=0, likeNumber=84, createdTime=2024-01-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5f0581138308, moduleTitle=ASCO GU 2024：ctDNA有望在睾丸癌预后评估方面发挥更精准的管理价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f0581138308)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184488, encodeId=7676218448832, content=<a href='/topic/show?id=3cc88658264' target=_blank style='color:#2F92EE;'>#舒尼替尼#</a> <a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a> <a href='/topic/show?id=c193110640f1' target=_blank style='color:#2F92EE;'>#ASCO GU 2024#</a>, objectTitle=ASCO GU 2024：纳武利尤单抗/卡博替尼治疗晚期肾癌优于舒尼替尼（CheckMate-9ER 研究）, objectType=article, longId=811384, objectId=440881138441, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240128/1706443016945_8624274.png, objectUrl=/article/show_article.do?id=440881138441, replyNumber=0, likeNumber=0, createdTime=2024-01-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=440881138441, moduleTitle=ASCO GU 2024：纳武利尤单抗/卡博替尼治疗晚期肾癌优于舒尼替尼（CheckMate-9ER 研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=440881138441)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184496, encodeId=5dbf218449665, content=<a href='/topic/show?id=8f5c82594d5' target=_blank style='color:#2F92EE;'>#肾癌#</a> <a href='/topic/show?id=8d16999eda' target=_blank style='color:#2F92EE;'>#Ipilimumab#</a> <a href='/topic/show?id=30fc1282896' target=_blank style='color:#2F92EE;'>#Nivolumab#</a> <a href='/topic/show?id=c193110640f1' target=_blank style='color:#2F92EE;'>#ASCO GU 2024#</a>, objectTitle=ASCO GU 2024：Nivolumab/Ipilimumab在未经治疗的晚期或转移性RCC患者中显示出显著的生存获益（CheckMate-214研究）, objectType=article, longId=811385, objectId=df7281138559, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240128/1706443016945_8624274.png, objectUrl=/article/show_article.do?id=df7281138559, replyNumber=0, likeNumber=91, createdTime=2024-01-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=df7281138559, moduleTitle=ASCO GU 2024：Nivolumab/Ipilimumab在未经治疗的晚期或转移性RCC患者中显示出显著的生存获益（CheckMate-214研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df7281138559)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯管理员

睾丸癌 ctDNA ASCO GU 2024

2024-01-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#高危前列腺癌# #ASCO GU 2024# #大剂量放射治疗#

ASCO GU 2024：大剂量放射治疗或可延长高危前列腺癌患者的生存期

2024-01-30发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肾上腺癌# #ASCO GU 2024#

2024 ASCO GU｜肾上腺癌重磅研究出击，速览最新进展！

2024-01-30发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#依维莫司# #Belzutifan# #ASCO GU 2024# #晚期RCC#

ASCO GU 2024：Belzutifan与依维莫司对晚期RCC的疗效：LITESPARK-005 3 期研究中的患者报告结果 (PROs)

2024-01-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#睾丸癌# #ctDNA# #ASCO GU 2024#

ASCO GU 2024：ctDNA有望在睾丸癌预后评估方面发挥更精准的管理价值

2024-01-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#舒尼替尼# #卡博替尼# #纳武利尤单抗# #ASCO GU 2024#

ASCO GU 2024：纳武利尤单抗/卡博替尼治疗晚期肾癌优于舒尼替尼（CheckMate-9ER 研究）

2024-01-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肾癌# #Ipilimumab# #Nivolumab# #ASCO GU 2024#

ASCO GU 2024：Nivolumab/Ipilimumab在未经治疗的晚期或转移性RCC患者中显示出显著的生存获益（CheckMate-214研究）

2024-01-28发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务